-

INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Owlet, Inc. (OWLT) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT). The investigation concerns whether Owlet has violated the federal securities laws and/or engaged in other unlawful business practices.

On October 4, 2021, Owlet disclosed that it had received a warning letter from the U.S. Food and Drug Administration (“FDA”), which stated that “the Company’s marketing of its Owlet Smart Sock product . . . renders [it] a medical device requiring premarket clearance or approval from FDA.” Owlet has not obtained such clearance or approval. The Company also disclosed that the FDA “request[ed] the Company cease commercial distribution of the Smart Sock for uses in measuring blood oxygen saturation and pulse rate where such metrics are intended to identify or diagnose desaturation and bradycardia using an alarm functionality to notify users that measurements are outside of preset values.” On this news, the Company’s share price declined by $1.29 per share, or approximately 23.5%, from $5.48 per share to close at $4.19 per share on October 4, 2021.

If you purchased or otherwise acquired Owlet securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:OWLT

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

RAL INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Ralliant Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Ralliant Corporation (“Ralliant” or the “Company”) (NYSE:RAL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 4, 2026, Ralliant reported fourth quarter and full year 2025 results, revealing a “$1.4 billion non-cas...

KDDIY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving KDDI Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of KDDI Corporation (“KDDI” or the “Company”) (OTC:KDDIY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 6, 2026, KDDI posted an announcement on its website entitled “Notice Regarding Expectation that Disclosure of...

INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive (“the Class Period”). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app...
Back to Newsroom